The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
AACR 2020 | Can we use CH assessment to predict the risk of therapy-related myeloid neoplasms?
Featured:
Kelly BoltonThe AML Hub was pleased to speak to Kelly Bolton, Memorial Sloan Kettering Cancer Center, New York, US, during the American Association of Cancer Research (AACR) virtual meeting, about the use of assessment of clonal hematopoiesis (CH) to predict the risk of therapy-related myeloid neoplasms.
Kelly Bolton reported the results of a study investigating the relationship between CH and oncologic therapy in a large cohort of patients (N = 24,354) with solid tumors and available sequencing data. Then, she talked about CH and therapy-related myeloid neoplasm (tMN) risk and about the use of CH assessment to predict the risk for tMN.
Can we use CH assessment to predict the risk of therapy-related myeloid neoplasms?